Latest & greatest articles for simvastatin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on simvastatin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on simvastatin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for simvastatin

81. Cost effectiveness of micronised fenofibrate and simvastatin in the short term treatment of type IIa and type IIb hyperlipidaemia

Cost effectiveness of micronised fenofibrate and simvastatin in the short term treatment of type IIa and type IIb hyperlipidaemia Cost effectiveness of micronised fenofibrate and simvastatin in the short term treatment of type IIa and type IIb hyperlipidaemia Cost effectiveness of micronised fenofibrate and simvastatin in the short term treatment of type IIa and type IIb hyperlipidaemia Kirchgassler K U, Schiffner-Rohe J, Stahlheber U Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Micronised Fenofibrate and Simvastatin in the treatment of type IIa and IIb hyperlipidaemia. Type of intervention Treatment; Secondary prevention. Economic study type Cost-effectiveness analysis. Study population Patients (median age 51 years

NHS Economic Evaluation Database.1997

82. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease

Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease Johannesson M, Jonsson B, Kjekshus J, Olsson A G, Pedersen T R, Wedel H Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Using simvastatin (Zocor, Merck) for reducing cholesterol levels in patients with coronary heart disease (CHD). Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population Patients 35 to 70 years of age with total cholesterol levels

NHS Economic Evaluation Database.1997

83. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women.

Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. 9271481 1997 09 04 1997 09 04 2013 11 21 0028-4793 337 9 1997 Aug 28 The New England journal of medicine N. Engl. J. Med. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. 595-601 Postmenopausal estrogen therapy has favorable effects on serum lipoproteins in women with normal serum lipid levels, but the effect of combined estrogen and progestin (...) therapy on lipoproteins in women with hypercholesterolemia has not been determined, nor has it been directly compared with the effect of conventional lipid-lowering therapy. In a randomized crossover trial, we studied 58 postmenopausal women with fasting serum total cholesterol levels greater than 250 mg per deciliter. Each woman received simvastatin (10 mg daily) for eight weeks and postmenopausal hormone therapy (up to 1.25 mg of conjugated equine estrogens daily, along with 5 mg

NEJM1997

84. Cholesterol lowering and the use of healthcare resources: results of the Scandinavian Simvastatin Survival Study

Cholesterol lowering and the use of healthcare resources: results of the Scandinavian Simvastatin Survival Study Cholesterol lowering and the use of healthcare resources: results of the Scandinavian Simvastatin Survival Study Cholesterol lowering and the use of healthcare resources: results of the Scandinavian Simvastatin Survival Study Pedersen T R, Kjekshus J, Berg K, Olsson A G, Wilhelmsen L, Wedel H, Pyorala K, Miettinen T, Haghfelt T, Faergeman O, Thorgeirsson G, Jonsson B, Schwartz J S (...) Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Simvastatin (HMG coenzyme A-inhibitor) in patients with cardiovascular disease. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study

NHS Economic Evaluation Database.1996

85. Cost-effectiveness of cholesterol lowering: results from the Scandinavian Simvastatin Survival Study (4S)

Cost-effectiveness of cholesterol lowering: results from the Scandinavian Simvastatin Survival Study (4S) Cost-effectiveness of cholesterol lowering: results from the Scandinavian Simvastatin Survival Study (4S) Cost-effectiveness of cholesterol lowering: results from the Scandinavian Simvastatin Survival Study (4S) Jonsson B, Johannesson M, Kjekshus J, Olsson A G, Pedersen T R, Wedel H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Simvastatin 10, 20 or 40mg/day for the prevention of coronary events and death in patients with established coronary heart disease. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population Patients with prior myocardial infarction (MI) or

NHS Economic Evaluation Database.1996

86. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)

Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S) 7746058 1995 06 15 1995 06 15 2015 06 16 0140-6736 345 8960 1995 May 20 Lancet (London, England) Lancet Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S) 1274-5 We examined the relation between the risk of major coronary events (coronary death and non-fatal myocardial infarction) and baseline cholesterol levels in patients with coronary (...) heart disease, randomised to placebo or simvastatin therapy in the Scandinavian Simvastatin Survival Study (4S). The relative risk reduction in the simvastatin group was 35% (95% CI 15-50) in the lowest quartile of baseline low-density-lipoprotein cholesterol and 36% (19-49) in the highest. Simvastatin significantly reduced the risk of major coronary events in all quartiles of baseline total, high-density-lipoprotein, and low-density-lipoprotein cholesterol, by a similar amount in each quartile. eng Clinical Trial

Lancet1995

87. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) 7968073 1994 12 16 1994 12 16 2015 06 16 0140-6736 344 8934 1994 Nov 19 Lancet (London, England) Lancet Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) 1383-9 Drug therapy for hypercholesterolaemia has remained controversial mainly because of insufficient clinical trial (...) evidence for improved survival. The present trial was designed to evaluate the effect of cholesterol lowering with simvastatin on mortality and morbidity in patients with coronary heart disease (CHD). 4444 patients with angina pectoris or previous myocardial infarction and serum cholesterol 5.5-8.0 mmol/L on a lipid-lowering diet were randomised to double-blind treatment with simvastatin or placebo. Over the 5.4 years median follow-up period, simvastatin produced mean changes in total cholesterol

Lancet1994

88. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)

Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS) 7864934 1994 09 23 1994 09 23 2015 06 16 0140-6736 344 8923 1994 Sep 03 Lancet (London, England) Lancet Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS) 633-8 It has yet to be established whether substantial reduction of plasma lipids will lead to retardation, and to what extent and how quickly, of diffuse and focal coronary atheroma. The Multicentre Anti-Atheroma Study (...) (MAAS) is a randomised double-blind clinical trial of 381 patients with coronary heart disease assigned to treatment with diet and either simvastatin 20 mg daily or placebo for 4 years. Patients on simvastatin had a 23% reduction in serum cholesterol, a 31% reduction in low-density lipoprotein cholesterol, and a 9% increase in high-density lipoprotein cholesterol compared with placebo over 4 years. Quantitative coronary angiography was done at baseline, and after 2 and 4 years. 167 patients (89

Lancet1994

89. Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome.

Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome. 2904053 1989 01 10 1989 01 10 2015 06 16 0140-6736 2 8624 1988 Dec 10 Lancet (London, England) Lancet Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome. 1335-8 The efficacy, safety, and tolerability of simvastatin (20 mg twice a day) in the treatment of hyperlipidaemia due to unremitting nephrotic syndrome was compared (...) with that of cholestyramine (8 g twice a day) in a crossover trial in ten patients. Two patients were taken off the protocol, one because he could not tolerate cholestyramine and one because of non-compliance with the cholestyramine regimen. No clinical or laboratory adverse experiences were noticed during the study in the other eight patients. Simvastatin was significantly more effective than cholestyramine in reducing the hyperlipidaemia--it produced a 36% decrease in total cholesterol and a 39% decrease in low density

Lancet1988

90. Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia.

Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia. 2894548 1988 04 19 1988 04 19 2015 06 16 0140-6736 1 8586 1988 Mar 19 Lancet (London, England) Lancet Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia. 611-3 The ability of simvastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, to lower lipid (...) levels in 16 patients with primary hypercholesterolaemia was compared with that of bezafibrate in a 16-week, double-blind, parallel, placebo-controlled trial that was continued in an open crossover fashion. Simvastatin was better than bezafibrate at lowering total and low-density lipoprotein (LDL)-cholesterol and apolipoprotein B concentrations (30.4% [p less than 0.001], 37.3% [p less than 0.001], and 37.8% [p less than 0.001] vs 17.0%, 19.6%, and 24.0%, respectively). Both drugs increased

Lancet1988